Media Center

Search publications

Our news

All news

Media about us

  • 17 May 2017

    Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle

    John Carroll / Endpoints News

    Briggs Morrison has good reason today to be glad he left the Big Pharma R&D world behind at AstraZeneca and switched to biotech. The CEO of Waltham, MA-based Syndax reported that the company’s lead drug in combination with Merck’s Keytruda cleared its first big hurdle in Phase II and will now transition into the second phase of the study.

  • 02 May 2017

    Epic Sciences nets $40M for cancer liquid biopsy

    Amirah Al Idrus / FierceBiotech

    Epic Sciences raised $40 million in a Series D round, which it will use to ramp up clinical studies of its liquid biopsy tests that identify cancer patients who will benefit from specific treatments.

  • 02 May 2017

    Biopharma just can’t get enough of Epic Sciences

    Juliet Preston / MedCityNews

    Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round, a whopping 42 industry partnerships and over 200 clinical trials in the works, all built around its novel liquid biopsy platform. For a team of just 70, the San Diego, California startup is doing pretty well.

  • 02 May 2017

    With $40M in New Cash, Epic Sciences Advances Diagnostic for Late-Stage Prostate Cancer

    Bruce V. Bigelow / Xconomy

    When San Diego’s Epic Sciences raised $30 million almost three years ago, CEO Murali Prahalad told me he saw a big opportunity to use the company’s technology as a diagnostic test to assess how well a cancer patient is responding to specific anti-cancer drug regimens.

All publications

Portfolio companies news

All news

In the Spotlight

Read more

Industry news

All news